{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:02:26Z","timestamp":1792800146604,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100018283","name":"The 5th District Eagles Cancer Telethon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018283","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021070","name":"Fulbright Commission the Netherlands Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011475","name":"Cholangiocarcinoma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011475","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015724","name":"Mayo Clinic Minnesota Center for Cell Signaling in Gastroenterology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015724","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jhep.2024.02.008","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T03:44:31Z","timestamp":1709783071000},"page":"892-903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"80","author":[{"given":"Jennifer L.","family":"Tomlinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8572-8003","authenticated-orcid":false,"given":"Binbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3650-8100","authenticated-orcid":false,"given":"Emilien","family":"Loeuillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7726-5750","authenticated-orcid":false,"given":"Hannah E.","family":"Stumpf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3284-8773","authenticated-orcid":false,"given":"Hendrien","family":"Kuipers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7061-3238","authenticated-orcid":false,"given":"Ryan","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Willhite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0740-7447","authenticated-orcid":false,"given":"Daniel R.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8686-4867","authenticated-orcid":false,"given":"Rondell P.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory L.","family":"Smoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-009X","authenticated-orcid":false,"given":"Gregory J.","family":"Gores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2709-3003","authenticated-orcid":false,"given":"Sumera I.","family":"Ilyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.02.008_bib1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2024.02.008_bib2","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1172\/JCI137110","article-title":"Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"Loeuillard","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2024.02.008_bib3","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jhep.2023.05.010","article-title":"Immunobiology of cholangiocarcinoma","volume":"79","author":"Tomlinson","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.02.008_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2024.02.008_bib5","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/hep.27687","article-title":"IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism","volume":"61","author":"Yamada","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.02.008_bib6","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jcmgh.2021.05.011","article-title":"Anti-PD-1 in combination with trametinib suppresses tumor growth and improves survival of intrahepatic cholangiocarcinoma in mice","volume":"12","author":"Wabitsch","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.02.008_bib7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jhep.2019.05.027","article-title":"Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis","volume":"71","author":"Wang","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.02.008_bib8","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2024.02.008_bib9","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.18632\/oncotarget.23638","article-title":"YAP-associated chromosomal instability and cholangiocarcinoma in mice","volume":"9","author":"Rizvi","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2024.02.008_bib10","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/0008-5472.CAN-11-3596","article-title":"Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma","volume":"72","author":"O'Dell","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2024.02.008_bib11","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/gutjnl-2021-324109","article-title":"GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity","volume":"71","author":"Ruffolo","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.02.008_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4049\/immunohorizons.2200054","article-title":"A\u00a0novel humanized PD-1\/PD-L1 mouse model permits direct comparison of antitumor immunity generated by food and drug administration-approved PD-1 and PD-L1 inhibitors","volume":"7","author":"Barham","year":"2023","journal-title":"Immunohorizons"},{"key":"10.1016\/j.jhep.2024.02.008_bib13","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41575-022-00739-y","article-title":"Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance","volume":"20","author":"Calvisi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.02.008_bib14","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.celrep.2017.06.008","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"19","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2024.02.008_bib15","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2024.02.008_bib16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2024.02.008_bib17","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/ng.3441","article-title":"Clock-like mutational processes in human somatic cells","volume":"47","author":"Alexandrov","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2024.02.008_bib18","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/0008-5472.CAN-21-2556","article-title":"In\u00a0vivo modeling of patient genetic heterogeneity identifies new ways to target cholangiocarcinoma","volume":"82","author":"Younger","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2024.02.008_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2024.02.008_bib20","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1038\/s41467-018-06654-8","article-title":"TGF-beta-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2024.02.008_bib21","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1038\/s41467-020-18617-z","article-title":"Bone morphogenetic protein 7 promotes resistance to immunotherapy","volume":"11","author":"Cortez","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2024.02.008_bib22","article-title":"Tumors establish resistance to immunotherapy by regulating T(reg) recruitment via CCR4","volume":"8","author":"Marshall","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jhep.2024.02.008_bib23","article-title":"Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer","volume":"9","author":"Li","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jhep.2024.02.008_bib24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41419-019-1748-1","article-title":"Hypoxia-induced ZEB1 promotes cervical cancer progression via CCL8-dependent tumour-associated macrophage recruitment","volume":"10","author":"Chen","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jhep.2024.02.008_bib25","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","article-title":"Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications","volume":"72","author":"Martin-Serrano","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.02.008_bib26","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2024.02.008_bib27","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ajpath.2013.12.002","article-title":"Hydrodynamic transfection for generation of novel mouse models for liver cancer research","volume":"184","author":"Chen","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2024.02.008_bib28","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1172\/JCI63212","article-title":"Cholangiocarcinomas can originate from hepatocytes in mice","volume":"122","author":"Fan","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2024.02.008_bib29","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.27992","article-title":"YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors","volume":"62","author":"Marti","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.02.008_bib30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00535-019-01563-z","article-title":"YAP and the Hippo pathway in cholangiocarcinoma","volume":"54","author":"Sugihara","year":"2019","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2024.02.008_bib31","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1053\/j.gastro.2005.03.010","article-title":"Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells","volume":"128","author":"Kobayashi","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.02.008_bib32","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3748\/wjg.v25.i5.608","article-title":"Analysis of intrahepatic sarcomatoid cholangiocarcinoma: experience from 11 cases within 17 years","volume":"25","author":"Kim","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2024.02.008_bib33","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2024.02.008_bib34","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2024.02.008_bib35","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/JCO.2023.41.4_suppl.531","article-title":"Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"41","author":"Bouattour","year":"2023","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824001272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824001272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T21:26:13Z","timestamp":1715808373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824001272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0168827824001272"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.02.008","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}